Showing results (641-650 of 9,400) with videos related to
Sort By:
Pageof 940
Clinical Pharmacology and Therapeutics|June 28, 2018
Cinnamon and Cassia Nomenclature Confusion: A Challenge to the Applicability of Clinical DataHellen A Oketch-Rabah, Robin J Marles, Josef A BrinckmannClinical Pharmacology and Therapeutics|April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With CancerB S Adiwijaya, J Kim, I Lang, et al.Clinical Pharmacology and Therapeutics|September 13, 2016
A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung CancerG K Raju, K Gurumurthi, R Domike, et al.Clinical Pharmacology and Therapeutics|September 13, 2016
Competitive Development in Pharmacologic Classes: Market Entry and the Timing of DevelopmentJ A DiMasi, R ChakravarthyClinical Pharmacology and Therapeutics|November 1, 1978
(-)-2-Hydroxy-n-cyclopropylmethylmorphinan: radioimmunoassay and phamacokinetic profileR Dixon, R Young, E Mohacsi, et al.Clinical Pharmacology and Therapeutics|May 9, 2018
Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular DiseasesBenoit J Arsenault, Nicolas Perrot, Rishi PuriClinical Pharmacology and Therapeutics|July 13, 2017
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in OncologyRemy B Verheijen, Huixin Yu, Jan H M Schellens, et al.Clinical Pharmacology and Therapeutics|April 20, 2018
A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin-I in Subjects With Stable Cardiovascular DiseaseMathijs C Bodde, Paul Welsh, Sandrin C Bergheanu, et al.Clinical Pharmacology and Therapeutics|April 20, 2018
Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover TrialMaria O Kovalchuk, Jules A A C Heuberger, Boudewijn T H M Sleutjes, et al.Clinical Pharmacology and Therapeutics|July 1, 1988
Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virusJ Sjövall, A Karlsson, S Ogenstad, et al.Pageof 940